Test of Preimplantation Genetic Testing for Aneuploidies
| Test Code | EA |
|---|---|
| Test Summary | Preimplantation Genetic Testing for aneuploidies. |
| Turn Around Time | 10 days |
| Acceptable Sample Types | Blastocyst |
| NY Approved | No |
*TAT starts after the sample and all required sample information is received at the processing laboratory.
**The CPT codes listed are in accordance with Current Procedural Terminology, a publication of the American Medical Association, and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party.
This testing service has not been cleared or approved by the U.S. Food and Drug Administration. Testing services may not be licensed in accordance with the laws in all countries. The availability of specific test offerings is dependent upon laboratory location.
**The CPT codes listed are in accordance with Current Procedural Terminology, a publication of the American Medical Association, and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party.
This testing service has not been cleared or approved by the U.S. Food and Drug Administration. Testing services may not be licensed in accordance with the laws in all countries. The availability of specific test offerings is dependent upon laboratory location.
This test is not available in your region Japan, please select your nearest laboratory to request more information.
Revvity Sites Globally
Select your location.
Test Code:
EA
Test Description
Preimplantation Genetic Testing for aneuploidies (PGT-A) is that before implantation, detecting the abnormal number of chromosomes 1-22 and X/Y, indicating micro-deletion and micro-duplication abnormalities >4Mb.
Indications for Testing
- Women at an elder age.
- Repeated natural abortion for unknown reasons.
- Repeated implantation failure for unknown reasons.
- Severe teratospermia.
Test Methods and Limitations
This test analyzes picogram quantities of DNA (single/multi-cells or low template DNA) from an embryo biopsy for preimplantation genetic testing by whole genome amplification (WGA) and next generation sequencing (NGS) technology, to accurately screen all 24 chromosomes for whole chromosome aneuploidy and sub-chromosomal abnormalities.